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This study was conducted to compare the diagnostic performance and early recurrence rate
between gadoxetic acid–enhanced magnetic resonance imaging (Gd-EOB-MRI) and mag-
netic resonance imaging (MRI) with extracellular contrast agent (ECA-MRI) for evaluating
hepatic lesions in colorectal cancer.
Materials and Methods
Between 2005 and 2010, 418 colorectal cancer patients with both preoperative computed
tomography (CT) and liver MRI were retrospectively reviewed. Image analysis was based on
initial radiologic reports, and diagnostic performance was assessed based on the area under
the receiver operating characteristic curve (AUROC). The early intrahepatic recurrence rate
within 6 months was then evaluated.
Results
Overall, 291 and 127 patients underwent Gd-EOB-MRI and ECA-MRI, respectively. The 
AUROCs were not significantly different between Gd-EOB-MRI (0.990; 95% CI, 0.980 to
0.999) and ECA-MRI (0.985; 95% CI, 0.968 to 1.000; p=0.836). When compared with CT
alone, ECA-MRI detected additional 21 lesions in 14 patients (14/127, 11.0%), whereas
Gd-EOB-MRI detected 56 lesions in 33 patients (33/291, 11.3%) without a significant dif-
ference between two MRI groups (p=0.331). The early recurrence rate in the ECA-MRI 
(28.6%) was significantly higher than that in the Gd-EOB-MRI (11.6%) for patients who 
underwent hepatic resection (p=0.031).
Conclusion
Gd-EOB-MRI is potentially better than ECA-MRI for decreasing the early intrahepatic recur-
rence rate, although the two MRI modalities showed comparable diagnostic performance
in colorectal cancer patients.
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Introduction
The liver is the most common organ of distant metastasis
in colorectal cancer, and approximately 15%-20% of patients
present with liver metastasis at the initial staging [1,2]. 
Because colorectal liver metastasis (CRLM) is an important
prognostic factor and surgical resection can improve survival
in suitable patients [3,4], accurate staging is essential for the
proper management of and improvement of survival in these
patients. Most colorectal cancer patients undergo computed
tomography (CT) for evaluation of the initial disease status,
including that of the liver [5-7]. However, CT has inherent
limitations when applied for detecting and characterizing
small hepatic lesions (< 1 cm), as well as for detecting hepatic
lesions in the fatty liver [7,8]. 
The majority of the current clinical guidelines, including
the National Comprehensive Cancer Network guidelines, do
not necessitate the use of magnetic resonance imaging (MRI)
for evaluation of CRLM. However, MRI is a widely used
problem-solving tool during evaluation of the liver in col-
orectal cancer. MRI not only increases the confidence in 
diagnosing small indeterminate lesions detected on CT [9,10]
but also detects additional CRLM, especially for lesions 
< 1 cm [11-13]. After its initial approval in Europe in 2004,
gadoxetic acid (Primovist, Bayer Schering Pharma, Berlin,
Germany; Eovist, Bayer Healthcare Pharmaceuticals, Whip-
pany, NJ) was approved in many Asian countries at 2007 and
the United States at 2008, and has since been widely applied
for liver MRI. Many studies have shown that gadoxetic acid–
enhanced MRI (Gd-EOB-MRI) is superior to CT, and recent
consensus guidelines from the radiologic community recom-
mend Gd-EOB-MRI for the preoperative evaluation of
CRLM [14,15]. Gadoxetic acid has different pharmacokinetic
and pharmacodynamic properties from extracellular contrast
agents. Specifically, gadoxetic acid has the combined prop-
erties of an extracellular contrast agent during the early vas-
cular-interstitial phase and a liver-specific agent during the
delayed phase [16]. Because of the different properties and
variations in cost of contrast agents, evidence-based infor-
mation is needed to enable decision making regarding which
contrast agent should be used in patients with CRLM. 
To the best of our knowledge, there is no solid evidence of
the clinical benefits of Gd-EOB-MRI over MRI with an extra-
cellular contrast agent (ECA-MRI) in this setting. Therefore,
we retrospectively compared the effectiveness of Gd-EOB-
MRI and ECA-MRI in CRLM in terms of diagnostic perform-
ance and early intrahepatic recurrence rate.
Materials and Methods
1. Patients
This retrospective cohort study was approved by our 
institutional review board, and the need for informed con-
sent was waived. Fig. 1 shows the flow of patient enrollment.
We searched the electronic medical records and found 3,549
patients who presented with newly diagnosed colorectal can-
cer between January 2005 and December 2010. The study 
period was selected to include patients who underwent 
Gd-EOB-MRI or ECA-MRI and had sufficient follow-up 
periods. Among these patients, 505 were excluded for the fol-
lowing reasons: (1) past or concurrent malignancy other than
colorectal cancer (n=308); (2) absence of operation for pri-
mary colorectal cancer (n=147); and (3) no contrast-enhanced
abdominopelvic CT prior to any treatment (n=50). Among
the remaining patients, 2,516 without contrast-enhanced liver
MRI before treatment and 110 who met the following criteria
were also excluded: (1) MRI contrast agent other than an 
extracellular agent or gadoxetic acid (n=38); (2) multiple 
hepatic lesions (> 10) on CT (n=23); (3) distant metastasis to
sites other than the liver (n=20); (4) interval between CT and
liver MRI of > 4 weeks (n=24); and (5) unavailable reference
standard for hepatic lesions (n=5). Finally, 418 colorectal can-
cer patients who underwent both abdominopelvic CT and
liver MRI before treatment were included. Demographic 
information including age, sex, serum carcinoembryonic
antigen (CEA) level, pathologic tumor node metastasis stag-
ing system, American Joint Committee on Cancer staging, 
location of the primary tumor, and differentiation of the pri-
mary tumor was reviewed, as well as whether liver operation
was performed. For patients who had undergone hepatic 
resection, the presence or absence of adjuvant chemotherapy
or radiotherapy was investigated.
2. CT and MRI acquisition
At our institution, liver MRI is generally performed for 
patients found to have potentially resectable liver metastases
on CT, according to the National Comprehensive Cancer
Network guidelines [5,6]. Liver MRI is also performed for
patients with an indeterminate lesion on CT or for high-risk
patients, at the discretion of surgeons and physicians.
All CT scans were performed with a 16-, 64-, or 128-chan-
nel multidetector (Siemens Healthcare, Erlangen, Germany;
GE Healthcare, Waukesha, WI). Portal-phase abdomino-
pelvic CT was obtained 70 seconds after the intravenous 
administration of 2.0 mL/kg nonionic contrast material 
(iopromide, Ultravist 300, Bayer Schering Pharma), followed
by a 20 mL saline chaser bolus injection at a fixed duration
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of 30 seconds. 
Liver MRI was performed with a 1.5-T (Philips Healthcare,
the Best, the Netherlands) or 3.0-T magnet (Siemens Health-
care, Philips Healthcare). Magnetic resonance (MR) sequ-
ences that were similar for ECA-MRI and Gd-EOB-MRI
included dual-echo in-phase and opposed-phase spoiled gra-
dient-echo T1-wei-ghted images, as well as multishot and
single-shot turbo spin-echo T2-weighted images. Dynamic
fat-suppressed spoiled gradient-echo T1-weighted images
were acquired before and after contrast material injection 
(arterial, portal venous, 3-minute delayed, and 5-minute 
delayed phases). For ECA-MRI, variable gadolinium-based
contrast agents, including gadopentetate dimeglumine (Mag-
nevist, Bayer Schering Pharma) and gadoterate meglumine
(Dotarem, Guerbet, Roissy, France), were used, and 0.1
mmol/kg gadolinium agent was administered intrave-
nously. For dynamic scan with gadoxetic acid disodium (Pri-
movist, Bayer Schering Pharma), 0.1 mL/kg (0.025 mmol/
kg) gadoxetic acid disodium was injected, and additional 
hepatobiliary phase images were obtained after 15 or 20 min-
utes. Gadoxetic acid has replaced extracellular contrast
agents for liver MRI at our institution since January 2008;
therefore, the decision to perform ECA-MRI or Gd-EOB-MRI
was not influenced by the patient or physician factor, but by
the study period.
Fig. 1. Flow of patient enrollment. CT, computed tomography; MRI, magnetic resonance imaging; ECA, extracellular contrast
agent; ECA-MRI, magnetic resonance imaging with extracellular contrast agent; Gd-EOB-MRI, gadoxetic acid–enhanced
magnetic resonance imaging.
Patients presented with newly diagnosed colorectal cancer
  between January 2005 and December 2010 (n=3,549)
  (source population)
Colorectal cancer patients with both pretreatment 
  abdominopelvic CT and liver MRI (n=418)
  (study population)
Colorectal cancer patients with pretreatment contrast-enhanced 
  abdominopelvic CT (n=3,044)
Exclusion criteria (n=505)    
  Past or concurrent other malignancy (n=308)
  Patients who did not undergo colorectal operation (n=147)
  No pre-treatment contrast-enhanced abdominopelvic CT (n=50)
Exclusion criteria (n=2,626)    
  No pretreatment contrast-enhanced liver MRI (n=2,516)
  MRI contrast other than ECA and gadoxetic acid (n=38)
  Suspected multiple metastasis (> 10) on CT (n=23)
  Distant metastasis other than liver (n=20)
  Interval between CT and MRI > 4 weeks (n=24)
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3. Image analysis
The CT and MRI images were prospectively interpreted as
the routine practice using a picture archiving and communi-
cation system by six board-certified abdominal radiologists
with 7 to 20 years of experience in liver imaging. Each focal
hepatic lesion was classified as follows: 1, definitely benign;
2, probably benign; 3, indeterminate; 4, probably metastatic;
and 5, definitely metastatic. Category 1 included typical 
benign lesions such as cyst, hemangioma, or calcification.
Category 2 included lesions that were judged to be more
likely benign than metastatic but the benignity was not 
definitive, whereas category 4 represented the opposite sit-
uation. Category 3 included tiny hepatic lesions or lesions
that were difficult to categorize as either benign or metasta-
tic. Category 5 was assigned to typical metastatic lesions.
Given this retrospective study design, a study coordinator
(N.S., a board-certified abdominal radiologist with a 3-year
non-trainee experience in liver imaging) rescored the lesion
category based on clinical radiologic reports. The study 
coordinator also reviewed the size, segmental location, and
number of the hepatic lesions on the basis of the initial radi-
ologic reports. Additional lesions detected on liver MRI com-
pared with CT alone were recorded in the same manner.
Only additional lesions of MRI category 3-5 were recorded,
while additionally detected definitely or probably benign 
lesions were not recorded.
4. Confirmation of hepatic lesions
The study coordinator assessed the hepatic outcomes. All
patients underwent surgery for primary colorectal cancer.
During the operation, the liver was assessed by manual pal-
pation and often with intraoperative ultrasonography (IOUS)
for suspected liver metastasis. IOUS was performed by
board-certified radiologists in 15.7% (20 of 127) of the ECA-
MRI group and 16.5% (69 of 291) of the Gd-EOB-MRI group.
In patients for which there were no pathological results for
hepatic lesions, hepatic outcome was determined through
follow-up imaging. On follow-up imaging, increase or 
decrease in the size of the hepatic lesions during chemother-
apy was considered metastasis. In contrast, the decrease in
size or disappearance of the hepatic lesion without treatment
was considered as benign. Lesions that remained stable for
at least 12 months were also considered benign. 
5. Follow-up
At our institution, patients underwent physical examina-
tions and measurement of CEA at 3-month intervals over 2
years, then at 6-month intervals during the next 3 years. Con-
trast-enhanced abdominopelvic CT and chest CT were per-
formed at 6- and 12-month intervals, respectively, during the
first 5 years after surgery. In patients with resected metasta-
sis, contrast-enhanced abdominopelvic CT and chest CT
were performed at shorter intervals of 3 and 6 months, 
respectively, during the first 2 years after surgery, then every
6 months up to a total 5 years. The dates of last follow-up
and intrahepatic recurrence were recorded. 
6. Statistical analysis
The data were analyzed in two separate groups. First, the
diagnostic performance for focal hepatic lesions was evalu-
ated in all study patients, and early intrahepatic recurrence
was evaluated for patients who were initially classified as
not having hepatic metastasis on preoperative imaging. Sec-
ond, the diagnostic performance and early intrahepatic 
recurrence were assessed in patients who underwent cura-
tive hepatic resection for suspected metastases.
The baseline demographics and characteristics of hepatic
lesions in the ECA-MRI and Gd-EOB-MRI groups were com-
pared by independent t tests for continuous variables, and
by Pearson’s chi-squared or Fisher exact test for categorical
variables. The diagnostic performance of MRI for predicting
liver metastasis was evaluated through receiver operating
characteristic (ROC) analysis. The area under the ROC curve
(AUROC) was reported with 95% confidence intervals (CIs).
Per-lesion and per-patient analyses were conducted. For the
per-lesion analysis, subgroup analysis was conducted for
small hepatic lesions ! 1 cm on MRI. The AUROC was com-
pared between ECA-MRI and Gd-EOB-MRI using chi-
squared statistics. The number and size of nodules that were
additionally detected on MRI compared to CT were com-
pared by the Mann-Whitney U test and independent t test,
respectively. 
The early intrahepatic recurrence rate was evaluated
through a competing risk analysis. Death of any cause was
considered a competing event, as death precludes the obser-
vation of recurrence. Early intrahepatic recurrence was 
defined as intrahepatic recurrence within 6 months of cura-
tive hepatic resection. For patients who did not undergo 
hepatic resection, early intrahepatic recurrence was defined
as recurrence within 6 months of colorectal surgery. The dif-
ferences in the cumulative incidence of tumor recurrence 
between ECA-MRI and Gd-EOB-MRI were compared by
Gray’s test [17]. Univariate and multivariate analyses were
performed with Fine and Gray’s subdistributional hazard 
regression model to identify independent prognostic factors
of early recurrence [18]. Multivariate analysis was performed
for factors with a p-value of < 0.1 on univariate analysis, and
clinically important factors (N stage, largest size and number
of metastasis, and type of MRI contrast agent). All statistical
analyses were conducted using SAS ver. 9.2 (SAS Institute
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Inc., Cary, NC), and a p < 0.05 was considered statistically
significant.
Results
1. Analysis of hepatic lesions from all patients
1) Patients
Of the 418 total patients, 127 (male:female [M:F], 67:60; mean
age±standard deviation [SD], 60±11.5 years) underwent ECA-
MRI and 291 (M:F, 171:120; 61.2±11.4 years) underwent 
Gd-EOB-MRI. No demographic data differed significantly 
between the ECA-MRI and Gd-EOB-MRI groups (Table 1).
Overall, 22% (28 of 127) and 29.6% (86 of 291) of patients in the
ECA-MRI and Gd-EOB-MRI groups underwent liver resec-
tion, respectively. The median time interval between CT and
liver MRI was 6 days (range, 0 to 28 days). 
2) Characterization and proof of hepatic lesions
A total of 635 hepatic lesions in 418 patients were confirmed
pathologically (n=285) or on follow-up imaging (n=350). For
pathologically confirmed lesions, the median time interval 
between MRI and biopsy or surgery was 8 days (range, 0 to
Table 1. Baseline characteristics of study population
Variable ECA-MRI (n=127) Gd-EOB-MRI (n=291) p-value
Age (yr) 60.0±11.5 61.2±11.4 0.33
Sex (male:female) 67 (52.8):60 (47.2) 171 (58.8):120 (41.2) 0.254
CEA (ng/dL) 13.9 ( 19.81 ( 0.373
T stage 
T1 5 (3.9) 19 (6.5) 0.516
T2 12 (9.4) 31 (10.7)
T3 88 (69.3) 203 (69.8)
T4 22 (17.3) 38 (13.1)
N stage
N0 57 (44.9) 200 (47.8) 0.71
N1 43 (33.9) 136 (32.5)
N2 27 (21.3) 82 (19.6)
M stage
M0 87 (68.5) 296 (70.8) 0.493
M1 40 (31.5) 122 (29.2)
AJCC stage
I 13 (10.2) 50 (12.0) 0.790
II 34 (26.8) 119 (28.5)
III 40 (31.5) 127 (30.4)
IV 40 (31.5) 122 (29.2)
Location of CRC
Colon 82 (64.6) 180 (61.9) 0.598
Rectum 45 (35.4) 111 (38.1)
Differentiation
Well 27 (21.3) 37 (12.7) 0.068
Moderately 90 (70.9) 234 (80.4)
Poorly or mucinous 10 (7.8) 20 (6.9)
Liver surgery
Yes 28 (22.0) 86 (29.6) 0.098
No 99 (78.0) 205 (70.4)
Values are presented as mean±standard deviation or number (%). ECA-MRI, magnetic resonance imaging with extracellular
contrast agent; Gd-EOB-MRI, gadoxetic acid–enhanced magnetic resonance imaging; CEA, carcinoembryonic antigen; AJCC,
American Joint Committee on Cancer; CRC, colorectal cancer. 
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29 days). Table 2 shows the characteristics of hepatic lesions
evaluated on ECA-MRI and Gd-EOB-MRI. The diameter of
the largest lesion and mean lesion number per patient did not
differ significantly between the ECA-MRI and Gd-EOB-MRI
groups (p=0.408 and p=0.102, respectively). The true hepatic
outcome and methods of lesion confirmation are demon-
strated in Fig. 2. Most benign lesions in the ECA-MRI (97.3%,
108 of 111) and Gd-EOB-MRI (93.8%, 212 of 226) groups were
confirmed on follow-up imaging, with a median follow-up 
period of 49 months (range, 13 to 97 months) and 55 months
(range, 16 to 84 months), respectively.
3) Diagnostic performance 
For per-patient analysis, the AUROC of ECA-MRI (0.985;
95% CI, 0.968 to 1.000) was not significantly different from that
of Gd-EOB-MRI (0.990; 95% CI, 0.980 to 0.999) (p=0.836). For
per-lesion analysis of the total 635 lesions, the AUROC 
Table 2. Characteristics of hepatic lesions evaluated on liver MRI
Variable ECA-MRI Gd-EOB-MRI p-value
Per-patient analysis
No. of patients 127 ( 291 (
Benign:Metastatic 85 (66.9):42 (33.1) 202 (69.4):89 (30.6) 0.614
The largest size of lesion (cm) 2.4±1.8 2.3±1.7 0.408
No. of lesions 1.7±1.0 1.3±0.8 0.102
Per-lesion analysis
No. of lesions 205 ( 430 (
Benign:Metastatic 111 (54.1):94 (45.9) 226 (52.6):204 (47.4) 0.772
Size of lesion, total (cm) 1.2±1.4 1.2±1.2 0.676
Benign (cm) 0.7±0.7 0.8±0.7 0.136
Metastatic (cm) 1.8±1.7 1.7±1.5 0.722
No. of lesions ! 1 cm (%) 118/205 (57.6) 227/430 (52.8) 0.259
Values are presented as number or mean±standard deviation. MRI, magnetic resonance imaging; ECA-MRI, MRI with extra-
cellular contrast agent; Gd-EOB-MRI, gadoxetic acid–enhanced MRI.
Fig. 2. Hepatic outcomes in study patients. This figure shows the true hepatic outcomes and methods of lesion confirmation
in study patients. Hepatic lesions were confirmed by surgery, biopsy, or follow-up imaging (F/U). ECA-MRI, magnetic res-
onance imaging with extracellular contrast agent; Gd-EOB-MRI, gadoxetic acid–enhanced magnetic resonance imaging.
ECA-MRI group (127 patients)
  205 hepatic lesions
Gd-EOB-MRI group (291 patients)
  430 hepatic lesions
Total 635 hepatic lesions (418 patients)
Benign lesions (n=111) Metastasis (n=94)
F/U (n=108) Surgery (n=2)
Biopsy (n=1)
F/U (n=20) Surgery (n=60)
Biopsy (n=14)
F/U (n=212) Surgery (n=9)
Biopsy (n=5)
F/U (n=27) Surgery (n=155)
Biopsy (n=22)
Benign lesions (n=226) Metastasis (n=204)
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Table 4. Baseline characteristics of patients who underwent liver surgery
Variable ECA-MRI (n=28) Gd-EOB-MRI (n=86) p-value
Age (yr) 57.4±11.2 58.8±11.9 0.602
Sex (male:female) 20 (71.4):8 (28.6) 51 (59.3):35 (40.7) 0.250
CEA (ng/dL)
! 5 17 (60.7) 49 (57) 0.728
> 5 11 (39.3) 37 (43)
T stage 
T1 0 ( 4 (4.7) 0.127
T2 0 ( 3 (3.5)
T3 26 (92.9) 60 (69.8)
T4 2 (7.1) 19 (22.1)
N status
Negative 8 (28.6) 24 (27.9) > 0.999
Positive 20 (71.4) 62 (72.1)
Location of CRC
Colon 19 (67.9) 57 (66.3) 0.878
Rectum 9 (32.1) 29 (33.7)
Differentiation
Well 3 (10.7) 11 (12.8) 0.626
Moderately 24 (85.7) 66 (76.7)
Poorly or mucinous 1 (3.6) 9 (10.5)
The largest size of lesion (cm) 
Mean±SD 2.2±1.9 2.3±1.7 0.850
! 5 27 (96.4) 80 (93.0) > 0.999
> 5 1 (3.6) 6 (7.0)
No. of lesions 
Mean±SD 2.6±1.8 2.2±1.5 0.218
1 8 (28.6) 45 (52.3) 0.029
> 1 20 (71.4) 41 (47.7)
Adjuvant chemotherapy
Yes 27 (96.4) 80 (93.0) > 0.999
No 1 (3.6) 6 (7.0)
Adjuvant radiotherapy
Yes 7 (25.0) 20 (23.3) 0.850
No 21 (75.0) 66 (76.7)
Values are presented as mean±standard deviation or number (%). ECA-MRI, magnetic resonance imaging with extracellular
contrast agent; Gd-EOB-MRI, gadoxetic acid–enhanced magnetic resonance imaging; CEA, carcinoembryonic antigen; CRC,
colorectal cancer; SD, standard deviation. 
Table 3. Additional lesions detected on liver MRI compared to CT 
Variable ECA-MRI Gd-EOB-MRI Total p-value
Per-patient analysis
No. of patients (%) 14/127 (11.0) 33/291 (11.3) 47/418 (11.2) 0.331
No. of lesions, median (range) 1 (1-4) 1 (1-6) 1 (1-6) 0.530
Per-lesion analysis
No. of additional lesions (%) 21/205 (10.2) 56/430 (13.0) 77/635 (12.1) 0.316
Size of additional lesions, mean±SD (cm) 0.7±0.3 0.6±0.4 0.7±0.7 0.495
MRI, magnetic resonance imaging; CT, computed tomography; ECA-MRI, MRI with extracellular contrast agent; Gd-EOB-
MRI, gadoxetic acid–enhanced MRI; SD, standard deviation.
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between ECA-MRI (0.980; 95% CI, 0.963 to 0.997). and 
Gd-EOB-MRI (0.988; 95% CI, 0.976 to 0.999) was not signifi-
cantly different (p=0.476). The AUROCs were also comparable
between ECA-MRI (0.975; 95% CI, 0.935 to 1.000) and Gd-EOB-
MRI (0.985; 95% CI, 0.956 to 1.000) (p=0.695) for the 345 
lesions ! 1 cm. 
4) Detection of additional nodules on MRI compared with
CT 
In 47 patients (11.2%, 47 of 418), 77 lesions were additionally
detected on liver MRI compared with CT (Table 3). ECA-MRI
detected an additional 21 lesions in 14 patients, whereas 
Gd-EOB-MRI identified 56 additional lesions in 33 patients,
without a significant difference between two MRI groups
(p=0.331). Among the 21 additional lesions on ECA-MRI, 17
were finally considered metastatic, while four were benign. Of
the 56 additional lesions on Gd-EOB-MRI, 48 were metastatic
and eight were benign. 
5) Early intrahepatic recurrence in patients considered not
to have hepatic metastasis
Eighty-five patients with ECA-MRI and 202 patients with
Gd-EOB-MRI were initially considered to have only benign
hepatic lesions on preoperative imaging. Among these 
patients, one in each MRI group developed early intrahepatic
recurrence. For the ECA-MRI group, one patient (1/85, 1.2%)
who had hepatic cysts on preoperative imaging developed 
hepatic, lymph nodes, and bone metastases at 6 months after
primary colorectal surgery. In the Gd-EOB-MRI group, one
patient (1/202, 0.5%) who had a hepatic cyst on preoperative
imaging developed hepatic and lung metastases at 4 months
after colorectal surgery. Comparison of the intrahepatic recur-
rence rate and analysis of independent predictors for intrahep-
atic recurrence between the two MRI groups could not be
performed due to the small number of positive events. 
2. Analysis of patients who underwent hepatic surgery
1) Patients
Among 114 patients who underwent curative liver surgery
for suspected hepatic metastases, 28 (M:F, 20:8; mean age±SD,
57.4±11.2 years) underwent ECA-MRI and 86 (M:F, 51:35;
58.8±11.9 years) underwent Gd-EOB-MRI. Although most 
demographic variables were not significantly different 
between groups (Table 4), the number of patients who had
more than one hepatic metastases was significantly greater in
the ECA-MRI than the Gd-EOB-MRI group (p=0.029). 
Variable
Univariate                                                                 Multivariate
SDHR (95% CI) p-value SDHR (95% CI) p-value
Age 1.020 (0.977-1.060) 0.430 - -
Sex (male vs. female) 2.310 (0.782-6.840) 0.130 - -
CEA 1.000 (0.998-1.010) 0.220 - -
T stage
T2 vs. T1 1.282 (0.082-20.040) 0.860 - -
T3 vs. T1 0.547 (0.066-4.510) 0.570 - -
T4 vs. T1 0.481 (0.049-4.770) 0.530 - -
N stage
N0 vs. N1-2 3.390 (0.798-14.400) 0.098 3.813 (0.830-17.511) 0.085
Location of CRC
Colon vs. rectum 1.330 (0.478-3.700) 0.590 - -
MRI contrast agent 
Gd-EOB vs. ECA 0.365 (0.146-0.915) 0.032 0.288 (0.110-0.757) 0.012
The largest size of lesion 0.851 (0.627-1.160) 0.300 0.888 (0.658-1.200) 0.440
Lesion number per patient 
1 vs. > 1 0.682 (0.271-1.720) 0.420 0.698 (0.482-1.012) 0.058
Chemotherapy 1.070 (0.131-8.630) 0.950 - -
Radiotherapy 1.250 (0.453-3.440) 0.670 - -
Table 5. Univariate and multivariate analysis of factors associated with early recurrence
SDHR, subdistributional hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; CRC, colorectal cancer; MRI,
magnetic resonance imaging; Gd-EOB, gadoxetic acid; ECA, extracellular contrast agent.
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2) Diagnostic performance 
The 114 patients who underwent liver surgery had 260 focal
hepatic lesions. For per-lesion analysis, the AUROC between
ECA-MRI (0.924; 95% CI, 0.818 to 1.000) and Gd-EOB-MRI
(0.914; 95% CI, 0.825 to 1.000) was not significantly different
(p=0.885). For the 99 lesions ! 1 cm, the AUROCs between
ECA-MRI (0.895; 95% CI, 0.752 to 1.000) and Gd-EOB-MRI
(0.894; 95% CI, 0.805 to 0.984) did not differ significantly
(p=0.993).
3) Early intrahepatic recurrence
The cumulative incidence of early intrahepatic recurrence
was significantly higher (p=0.031) in the ECA-MRI (28.6%)
than the Gd-EOB-MRI group (11.6%). The results of univariate
and multivariate analyses of factors associated with early 
intrahepatic recurrence are shown in Table 5. Differentiation
of the primary colorectal tumor was not included in the uni-
variate and multivariate analyses because of inhomogeneous
data distribution. The type of contrast agent (ECA vs. 
Gd-EOB) was the only significant variable predicting early 
intrahepatic recurrence on univariate analysis (subdistribu-
tional hazard ratio [SDHR], 0.365; 95% CI, 0.146 to 0.915)
(p=0.032). Multivariate analysis also revealed that the use of
Gd-EOB-MRI was a good prognostic factor (SDHR, 0.288; 95%
CI, 0.110 to 0.757) (p=0.012).
Discussion
The results of this study demonstrated that the overall 
diagnostic performance of ECA-MRI and Gd-EOB-MRI for
the evaluation of focal hepatic lesions in colorectal cancer 
before treatment did not differ significantly. In addition, the
detection rate of additional significant hepatic lesions on MRI
compared with CT was similar between groups. However,
the early intrahepatic recurrence rate for patients who 
underwent hepatic resection was significantly higher in
ECA-MRI (28.6%) than in Gd-EOB-MRI (11.6%) (p=0.031).
Several meta-analyses have described the diagnostic per-
formance of Gd-EOB-MRI for the detection of CRLM [19,20].
Chen et al. [19] reported that the pooled weighted sensitivity
of Gd-EOB-MRI for detecting liver metastases was 93% (95%
CI, 90 to 95). In a recent meta-analysis, Gd-EOB-MRI showed
an excellent per-lesion sensitivity of 91.2% (95% CI, 83.7 to
95.4) for detecting CRLM [20]. Several meta-analyses inves-
tigating the diagnostic performance of ECA-MRI were pub-
lished in 2010 [12,13]. Specifically, Floriani et al. [13] reported
that the per-lesion sensitivity of ECA-MRI for detecting
CLRM ranged from 81.9% to 91.3%, while another meta-
analysis demonstrated that the per-lesion mean sensitivity
of ECA-MRI was 79.8% (95% CI, 62.6 to 90.3) [12]. The results
of those studies suggest that Gd-EOB-MRI is better than
ECA-MRI for detecting CRLM. However, those meta-analy-
ses were primarily based on retrospective studies, and no 
direct comparison between Gd-EOB-MRI and ECA-MRI was
conducted in any of the original studies included in the meta-
analyses. Therefore, an intra-individual study comparing
Gd-EOB-MRI and ECA-MRI is necessary to obtain more 
robust results [19]. 
To the best of our knowledge, only one intra-individual
study prospectively compared Gd-EOB-MRI and ECA-MRI
for staging CRLM, and the results of this study confirmed
the higher efficacy of Gd-EOB-MRI based on the reduced
need for additional preoperative examination and fewer 
intraoperative plan modifications [9]. Thus, we hypothesized
that Gd-EOB-MRI would be superior to ECA-MRI for diag-
nosing CRLM. Although Gd-EOB-MRI was performed more
recently with advanced MR techniques, the diagnostic per-
formance of Gd-EOB-MRI was not significantly different
from that of ECA-MRI in our study. There are several possi-
ble explanations for these findings. First, with the exception
of the hepatobiliary phase, ECA-MRI and Gd-EOB-MRI
share most sequences. As MR interpretation in daily practice
encompasses all these sequences, the overall diagnostic per-
formance could be similar between the two MRI modalities.
Second, the image analysis conducted in the present study
was based on a clinical report. According to the previous
study [21], initial radiology reports tended to have better 
diagnostic performance than blinded expert interpretation.
The suggested hypothesis was that patient history and clin-
ical data as well as imaging findings might have been con-
sidered at the time of the initial reports [21]. Similarly, the
clinical information provided at the time of the MR interpre-
tation in our study may show the higher effectiveness of both
ECA-MRI and Gd-EOB-MRI. Finally, this study included
only liver MRI scans performed before treatment such as
chemotherapy. After neoadjuvant chemotherapy, detection
and characterization of hepatic lesions become more chal-
lenging because of the changes in treated lesions, as well as
in response to background parenchymal changes such as
steatohepatitis or sinusoidal obstruction syndrome [22,23].
Accordingly, further study is needed to compare the diag-
nostic efficacy of ECA-MRI and Gd-EOB-MRI in the post-
treatment setting.
Early recurrence after CRLM resection has been associated
with a poor patient prognosis following hepatectomy [24-27].
Therefore, reduction of the early recurrence rate is important
to improve patient outcomes and avoid unnecessary hepatic
resection. Several predictive factors for early recurrence of
CRLM have been identified [24,25,28]. According to a recent
Cancer Res Treat. 2018;50(1):60-70
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study of 6,025 patients, T3-4 primary tumors, synchronous
CRLM, > 3 CRLM, 0 mm margin liver resection, and associ-
ated intraoperative radiofrequency ablation were independ-
ent risk factors for early recurrence [24]. Other factors that
correlated with higher early recurrence rates include poor
differentiation of the primary tumor, bilobar metastases,
multiple metastases (" 8), microscopic positive surgical mar-
gin, and elevated CEA (> 15 ng/mL) [25-27]. Early recur-
rence can be either a regrowth of undetected micrometastasis
or true recurrence after complete metastasectomy; therefore,
preoperative radiologic evaluation may affect the early 
recurrence rate. However, the effects of the MRI contrast
agent on early recurrence have never been studied. We 
assumed that the hepatobiliary phase of Gd-EOB-MRI could
better detect subclinical metastasis than ECA-MRI, which is
supported by our results. The early intrahepatic recurrence
rate was lower in the Gd-EOB-MRI group than the ECA-MRI
group for patients who underwent hepatic resection, as well
as for those considered to have no hepatic metastasis on pre-
operative MRI, although statistical analysis was unavailable
in the latter group. Furthermore, the type of MRI contrast
agent was an independent predictor of early intrahepatic 
recurrence in our study. Gd-EOB-MRI could detect more
numbers of tiny metastases that could be missed on ECA-
MRI, which could lead to a more complete resection of sub-
clinical metastases in the Gd-EOB-MRI group. 
In the present study, ECA-MRI and Gd-EOB-MRI showed
discordant results in terms of diagnostic performance and
early intrahepatic recurrence rate. To accurately evaluate 
diagnostic performance, an unbiased estimate of the test’s
accuracy is needed [29]. Specifically, the true disease status
of each patient should be determined independently from
the imaging test results. However, in clinical practice, 
patients with a negative test result may not have undergone
a gold-standard treatment such as invasive surgery [29];
therefore, the estimated diagnostic performance of tests may
be biased [30]. From this perspective, the difference in early
recurrence between Gd-EOB-MRI and ECA-MRI may reflect
the diagnostic accuracy more realistically, and thus could be
more meaningful than a simple comparison of diagnostic
performance. 
It should be noted that this study has several limitations.
First, there was an inevitable selection bias owing to the ret-
rospective cohort design. Second, ECA-MRI and Gd-EOB-
MRI were performed in different patients at different
periods. Unapparent time-dependent biases such as changes
in surgical techniques or adjuvant chemotherapeutic regi-
men may have affected our results. In addition, although
most MR protocols were similar between MRI modalities,
diffusion-weighted imaging (DWI) was primarily included
in the Gd-EOB-MRI group, while only a small portion of
ECA-MRI group contained DWI. Nevertheless, the ECA-MRI
and Gd-EOB-MRI showed comparable diagnostic perform-
ance for evaluating CRLM, which suggests that DWI might
not affect the diagnostic performance in our study. Third, the
patients that were operated on in the ECA-MRI group had
more metastases than those in the Gd-EOB-MRI group. 
Although the lesion number was not a significant factor on
univariate and multivariate analyses, the different lesion
number between groups is one of the limitations that must
be considered when interpreting our results. Finally, most of
the benign lesions were not pathologically confirmed. How-
ever, the median follow-up period was long enough to con-
firm the benignity of the lesions.
In conclusion, Gd-EOB-MRI can potentially decrease the
early intrahepatic recurrence rate compared with ECA-MRI
after hepatic resection, although the two MRI modalities
showed comparable diagnostic performance in colorectal
cancer patients. Further prospective studies comparing the
survival outcome between Gd-EOB-MRI and ECA-MRI
should follow.
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